
CLAIMS

1. A compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable carrier or diluent, and optionally one or more additional therapeutic agents.

3. A compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for use in treating or preventing infections caused by bacteria.

4. The use of a compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment or prevention of infections caused by bacteria.

5. Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-positive bacterium selected from *Staphylococcus spp.*, *Streptococcus spp.*, *Propionibacterium spp.*, *Enterococcus spp.*, *Bacillus spp.*, *Corynebacterium spp.*, *Nocardia spp.*, *Clostridium spp.*, *Actinobacteria spp.*, and *Listeria spp.*.

6. Use or compound for use according to Claim 5, wherein bacteria is *Bacillus anthracis*.

7. Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by a Gram-negative bacterium selected from *Enterobactericeae*, *Bacteroidaceae*, *Vibrionaceae*, *Pasteurellae*, *Pseudomonadaceae*, *Neisseriaceae*, *Rickettsiae*, *Moraxellaceae*, any species of *Proteeae*, *Acinetobacter spp.*, *Helicobacter spp.*, and *Campylobacter spp.*.

8. Use or compound for use according to Claim 7, wherein the bacteria is *E. coli*, *Klebsiella pneumonia*, *Yersinia pestis* or *Francisella tularensis*.

9. Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by *K. pneumoniae*, *Salmonella*, *E. hirae*, *A. baumanii*, *M. catarrhalis*, *H. influenzae*, *P. aeruginosa*, *E. faecium*, *E. coli*, *S. aureus* or *E. faecalis*.

10. Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is caused by rickettsiae, chlamydiae, *Legionella spp.* or *Mycoplasma spp.*.

11. Compound for use according to Claim 3, or use according to Claim 4, wherein the infection is a skin infection, a respiratory tract infection, a hospital acquired infection, an intra-abdominal infection or a urinary tract infection.

12. Compound for use according to Claim 3, or use according to Claim 4, wherein the compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, is administered alone.

13. Compound for use according to Claim 3, or use according to Claim 4, wherein the compound as defined in Claim 1, or a pharmaceutically acceptable salt thereof, is administered in combination with one or more additional therapeutic agents.

14. A process for making a composition as defined in Claim 2, which process comprises mixing the compound as defined in Claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or diluent.